

Nieuwsbrief #14
October 2019



Executive committee

Prof. dr. C.J.M. Klijn
Drs. K.M. van Nieuwenhuizen
Drs. F.H.B.M. Schreuder
Dr. H.B. van der Worp

Participating centers




UMC Utrecht
Radboudumc
Rijnstate
OLVG West
Universitair Medisch Centrum
Groningen
Medisch Spectrum Twente
Albert Schweitzer Ziekenhuis
Amsterdam UMC, locatie AMC
Gelre Ziekenhuizen
Amphia Ziekenhuis
Maastricht Universitair Medisch
Centrum
Erasmus MC
Leids Universitair Medisch
Centrum
Elisabeth
Tweesteden Ziekenhuis
Zuyderland
Haaglanden Medisch Centrum

Dear colleague,

You are now reading the 14th APACHE-AF newsletter.


Trial update

Since our previous newsletter (July 2019) we have included **five new patients!** We would like to thank the teams from Jeannette Hofmeijer (Rijnstate hospital, 1 patient), Julia van Tuijl (Elisabeth-TweeSteden hospital, 2 patients), Henk Kerkhoff (Albert Schweitzer hospital, 1 patient) and Diederik Dippel (ErasmusMC, 1 patient) for their effort!



Baseline data

We have now included **75 out of 100 patients**. The average age of the participants is 77 years and 44% is female. A total of 37 patients (49%) are randomized for apixaban treatment. A lobar hematoma was present in 28 patients (37%). Most patients used vitamin-K antagonists at the time of their index hemorrhage (79%). Please remember that use of a DOAC at the index ICH is also permitted to include a patient in the APACHE-AF trial.



Each patient is important!

We aim to include 100 patients before December 31st 2019. This challenging goal can be achieved if each participating center will include at least 1 patient by the end of this year.

Please remember:

- Our website includes a page with information for possible participants (<http://apache-af.nl/voor-patienten/>), where the trial is explained in Dutch.
- Discuss the referral of eligible patients with hospitals within your region.
- Explaining clinical equipoise to a patient and their relatives can be difficult. Consider to watch the movie on how to discuss this at the [website](#) of the SoStart trial, with whom we closely collaborate.
- Do not hesitate to contact us to discuss possibly eligible patients (by mail on apache-af@umcutrecht.nl or by telephone 024-3610245).

Utrechtse Stroke Update

On September 27th, Karin Klijn gave a lecture at the Utrechtse Stroke Update on the dilemmas in patients who have an intracerebral hemorrhage while using oral anticoagulants because of atrial fibrillation.

Karin asked the audience to vote whether or not to resume anticoagulation in a female patient with atrial fibrillation, who probably has cerebral amyloid angiopathy based on the MRI findings. At the start of the lecture, the minority of the attending colleagues, mostly APACHE-AF coinvestigators, would include such a patient in the APACHE-AF trial. When Karin had finished the presentation and again asked the audience whether or not to include this patient, everyone agreed that it was safe but moreover also important to include such patients in

this trial.

If you want to read up on the background of the lecture, which was based on a paper by Biffi et al, please click [here](#).

Please remember to report SAEs within 24 hours after you became aware of an event in OpenClinica and e-mail the SAE to apache-af@umcutrecht.nl.

Regards,

Karin Klijn

Koen van Nieuwenhuizen

Floris Schreuder

Bart van der Worp